People · Operator
Named in public records as an officer, director or promoter · active 2013–2025 · Biotechnology, Other Technology, Manufacturing, Other Health Care
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Aerie Pharmaceuticals Inc | — | Biotechnology | Series D+ | $189.6M | $5.2B | 2014 |
| Ocular Therapeutix, Inc | — | Biotechnology | Series B | $81.0M | $1.5B | 2013 |
| Ocunexus Therapeutics, Inc. | — | Biotechnology | Series B | $53.2M | $292.3M | 2020 |
| Vision Path, Inc. | — | Other Technology | Series B | $26.5M | $304.6M | 2017 |
| InflammX Therapeutics, Inc. | — | Biotechnology | Series A | $15.4M | $156.2M | 2020 |
| Silk Technologies, Ltd. | — | Biotechnology | Series A | $5.0M | $180.8M | 2017 |
| Zilks Plus Resources LLC | — | Manufacturing | Seed | $3.1M | $4.6M | 2021 |
| Concierge Pediatrics Holdings, LLC | — | Other Health Care | Seed | $2.1M | $4.3M | 2023 |
Brian Levy at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Brian Levy on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| James Blair | 2 | 8 |
| Richard L Lindstrom | 2 | 8 |
| David Pool | 2 | 4 |
| John Anderson | 1 | 22 |
| Peter Thompson | 1 | 16 |
| FARHAD KHOSRAVI | 1 | 14 |
| Richard Lindstrom | 1 | 13 |
| Rick Heitzmann | 1 | 11 |
| Alan Crane | 1 | 9 |
| Amarpreet Sawhney | 1 | 8 |
| ANAND MEHRA | 1 | 7 |
| James Garvey | 1 | 6 |
| Joshua Kazam | 1 | 5 |
| Charles Warden | 1 | 5 |
| Steven Cagnetta | 1 | 5 |
| David Epstein | 1 | 5 |
| DENNIS HENNER | 1 | 5 |
| Matthew Cooper | 1 | 5 |
| Jesse Horwitz | 1 | 5 |
| Gerald Cagle | 1 | 4 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.